Abdul Hye at King’s College London and his colleagues have identified 10 proteins in blood that can predict who will develop Alzheimer’s disease a year after having mild memory problems. Its accuracy is almost 90 per cent. That could prove a huge boost for researchers seeking treatments.
So far, trials of Alzheimer’s drugs are thought to have failed because they have been given too late in the course of the disease to halt progression. The new blood test will initially be used to identify those people with mild cognitive impairment who are likely to get Alzheimer’s disease and so might be good candidates for clinical trials to find drugs that halt disease progression.
“Having a blood test is a really big step forward,” says team member Ian Pike of Proteome Sciences in Cobham, UK. “The most important thing we can do is get the correct patients into clinical trials so we can tell, for example, whether it is a drug that is slowing the progression of the disease or the fact that we just happen to have a group of patients who have a slow progressing form of the disease.”